Onconova Therapeutics, Inc. to Provide Corporate Update and Full Year 2018 Financial Results
March 19, 2019 07:30 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., March 19, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Therapeutics, Inc. to Participate at the 31st Annual ROTH Conference March 17-19, 2019 in Orange County, CA
March 12, 2019 07:30 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., March 12, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Therapeutics, Inc. to Present Corporate Update at the BIO CEO & Investor Conference in New York City
February 04, 2019 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company focused on...
Advancements in the Treatment of Myelodysplastic Syndromes and RAS-Mutated Lung Cancers to be Presented by Key Opinion Leaders on Thursday, February 7, 2019, in New York City
January 31, 2019 07:30 ET
|
Onconova Therapeutics, Inc.
Invitation-only breakfast event sponsored by Onconova Therapeutics will also be webcast, beginning at 8:00 a.m. EST NEWTOWN, Pa., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc....
Onconova Therapeutics, Inc. to Present at the NobleCON 15th Annual Investor Conference in Fort Lauderdale, FL
January 22, 2019 07:30 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical stage biopharmaceutical company focused on discovering and developing novel products to...
Onconova Therapeutics Promotes Dr. Steven M. Fruchtman to Chief Executive Officer
January 15, 2019 17:15 ET
|
Onconova Therapeutics, Inc.
Executive succession plan maintains momentum of recent significant advancesOnconova well-positioned to deliver key milestones in 2019 for both intravenous and oral rigosertib, as well as other...
Onconova Submits Special Protocol Assessment (SPA) to FDA for Phase 3 Trial of Oral Rigosertib in Combination with Azacitidine (Vidaza®) for First-Line Myelodysplastic Syndromes (MDS)
January 02, 2019 07:30 ET
|
Onconova Therapeutics, Inc.
SPA submitted to the FDA before year-end 2018, marking achievement of a key regulatory milestoneAdvancement of this Phase 3 program, in treatment-naïve higher risk first-line MDS patients, positions...
Onconova to Meet Investors and Potential Partners at China Focus and the 37th Annual J.P. Morgan Healthcare Conferences in San Francisco
December 31, 2018 07:30 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Dec. 31, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Welcomes Avi Oler, JD, MBA, as Vice President, Corporate Development and General Counsel
December 10, 2018 07:30 ET
|
Onconova Therapeutics, Inc.
Mr. Oler joins Onconova’s management team as Vice President, Corporate Development and General Counsel, after an impactful tenure at Spectrum PharmaceuticalsHiring reflects Onconova’s commitment to...
Onconova Highlights Results from Phase 2 Trial of Oral Rigosertib In Combination with Azacitidine (Vidaza®) in Myelodysplastic Syndromes (MDS) at the 2018 ASH Annual Meeting
December 03, 2018 07:30 ET
|
Onconova Therapeutics, Inc.
Overall response rate (ORR) of 90% reported in this multi-institutional Phase 2 study in hypomethylating agent (HMA) naïve patients, including Complete Remission (CR) rate of 34% ORR of 54% and...